TG

Tripti Goel

Active Director Director DIN 01994764
DIN 01994764 First appointment Jan 2007 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Jan 2007
Shareholding value •••• Premium profile

About Tripti Goel

Data last updated:

Tripti Goel is a Director at Ant Pharmacueticals Private Limited (since 2016), Director at Sparshmart Pharmaceuticals Private Limited (since 2020) and Additional Director at Elastage Lifescience Private Limited (since 2025), and holds 1 more current directorship. The companies operate in Pharma, Chemicals and Materials and Infrastructure and Utilities. The 3 current companies with reported revenue have a combined latest revenue of ₹2.87 Cr; the largest is Ant Pharmacueticals Private Limited at ₹1.79 Cr (FY 2025). Earlier, Tripti Goel was a Director at Adore Educare Private Limited (2007–2012).

DIN 01994764
Primary Designation Director
Industry Pharma
First Appointment 29 Jan 2007
Oldest Company Age 19 yrs
Largest company Ant Pharmacueticals Private Limited · ₹1.79 Cr (FY 2025)
Combined revenue ₹2.87 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ant Pharmacueticals Private Limited U51909MH2016PTC287985
Director28 Nov 20162016₹1.79 Cr (FY 2025)Active
Director06 Nov 20202007₹84.3 Lakh (FY 2025)Active
Elastage Lifescience Private Limited U51909DL2014PTC264865
Additional Director21 Jan 20252014₹23.8 Lakh (FY 2024)Active
Partner12 Aug 20262026Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Adore Educare Private Limited U80903DL2007PTC158477
Director29 Jan 20072007Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Tripti Goel

NameDINCompanyDesignation
Basant Goel02296435Ant Pharmacueticals Private Limited , Sparshmart Pharmaceuticals Private Limited and 1 moreDirector
Priya Singh06410928Agerasia Biofuels LlpDesignated Partner
Sucheta Garg01620975Agerasia Biofuels LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Elastage Lifescience Private Limited
Sparshmart Pharmaceuticals Private Limited
Ant Pharmacueticals Private Limited
Agerasia Biofuels Llp
Premium access

Shareholding and investment profile for Tripti Goel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tripti Goel

Tripti Goel currently holds 4 directorships: Ant Pharmacueticals Private Limited (Director, since 28 Nov 2016, revenue ₹1.79 Cr (FY 2025)); Sparshmart Pharmaceuticals Private Limited (Director, since 06 Nov 2020, revenue ₹84.3 Lakh (FY 2025)); Elastage Lifescience Private Limited (Additional Director, since 21 Jan 2025, revenue ₹23.8 Lakh (FY 2024)); Agerasia Biofuels Llp (Partner, since 12 Aug 2026).

Tripti Goel was first appointed on 29 Jan 2007 as Director at Adore Educare Private Limited. The most recent appointment on record is 12 Aug 2026 at Agerasia Biofuels Llp.

The 3 current companies of Tripti Goel that report revenue have a combined latest revenue of ₹2.87 Cr: Ant Pharmacueticals Private Limited ₹1.79 Cr (FY 2025); Sparshmart Pharmaceuticals Private Limited ₹84.3 Lakh (FY 2025); Elastage Lifescience Private Limited ₹23.8 Lakh (FY 2024).

Tripti Goel held 1 earlier board appointment: Adore Educare Private Limited (Director, 29 Jan 2007 to 26 Mar 2012).

The current boards of Tripti Goel's companies include Basant Goel (Ant Pharmacueticals Private Limited), Priya Singh (Agerasia Biofuels Llp), Sucheta Garg (Agerasia Biofuels Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available